<DOC>
	<DOC>NCT01915940</DOC>
	<brief_summary>The objective of this Phase 2 study is to evaluate whether the Bimatoprost Ocular Insert is non-inferior to that of timolol ophthalmic solution (0.5%) at 12 weeks.</brief_summary>
	<brief_title>Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Key Written informed consent Primary openangle glaucoma or ocular hypertension in both eyes Bestcorrected distance vision of 20/80 or better Stable visual field corneal thickness between 490620 micrometers Key Cuptodisc ratio greater than 0.8 significant risk of angle closure due to pupil dilation, defined as a Shaffer classification of less than grade 2 based on gonioscopy laser surgery for glaucoma/ocular hypertension on one or both eyes within the last 12 months past history of corneal refractive surgery past history of any incisional surgery for glaucoma at any time corneal abnormalities that would interfere with tonometry readings current participation in an investigational drug or device study or participation in such a study within 30 days of screening Inability to accurately evaluate the retina</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Primary Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>